Nipocalimab, an anti–neonatal Fc receptor blocker, inhibits transplacental IgG transfer and lowers maternal IgG levels. In an international, open-label, single-group, phase 2 study, we assessed ...

The Breakthrough Therapy Designation (BTD) for investigational nipocalimab in Sjögren's disease, a prevalent autoantibody disease with no approved advanced therapies, is supported by results from ...

The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

In this final part of a recent interview with Jonathan Strober, MD, UCSF Benioff Children's Hospital and phase 2/3 ...

Adults with moderately-to-severely active Sjögren's disease who received investigational FcRn blocker nipocalimab had improvements in disease activity scores at 24 weeks with accompanying ...

Nipocalimab 15mg/kg improved ClinESSDAI score compared with placebo (treatment difference -2.65; [90% CI, -4.03, -1.28]; P =.002). The Food and Drug Administration (FDA) has granted Breakthrough ...

Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMG a score in ...

SPRING HOUSE, Pa. - Johnson & Johnson (NYSE: NYSE:JNJ) has released new data on nipocalimab, an investigational drug with potential to treat diseases driven by immunoglobulin G (IgG) antibodies.

Patients receiving nipocalimab plus standard of care improved by 4.7 points on the MG-ADL score, significantly more than placebo, and that was from baseline over weeks 22, 23, and 24, so around 6 ...

March 18, 2025 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted investigational nipocalimab Fast Track designation (FTD ...